A great example of a game-changing lactase solution which truly addresses a market pain point
Swiss-Dutch company DSM-Firmenich has launched Maxilact Next – the latest addition to its highly-valued range of Maxilact lactase enzymes. The new solution is the most efficient and pure lactase now available on the market. Maxilact Next is around 25% faster than the former fastest market reference utilised for milk processing, reducing the hydrolysis time by 25% when dosed at the same level.
Maxilact Next empowers lactose-free dairy producers to optimise production, increase capacity and use raw materials more efficiently – all without affecting the taste of lactose-free applications. It joins the existing Maxilact range, an extensive portfolio of high-purity solutions based on the company’s more than 50 years’ experience leading lactose-free dairy production.
Forecasts predict that lactose-free dairy will achieve a CAGR more than double that of regular dairy between 2022 and 2026, eventually exceeding a value of €10.6 billion. This creates fresh opportunities for dairy producers while also emphasising the need for a swifter and more efficient production process. Manufacturers require first-class lactase solutions to optimise their raw material usage, increase yield and productivity and maintain the highest quality standards.
Image credit- shutterstock